After-hours movers: Oracle surges, Acadia Pharma slumps

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/12/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. MSFT
9. CRM
10. CRWV

Go back to After-hours movers: Oracle surges, Acadia Pharma slumps

Acadia Pharmaceuticals (ACAD) Stock Selloff Is Over Done Says UBS, 'the level of sell-off is surprising to us'

March 12, 2024 4:07 PM EDT

UBS analyst Ashwani Verma lowered the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $33.00 (from $35.00) while maintaining a Buy rating.

The analyst comments "NSS opp'y not seen as a major upside driver; Nuplazid long IP offsets NSS ACAD stock is down ~17% intraday... More

Oracle (ORCL) PT Raised to $142 at CFRA

March 12, 2024 9:30 AM EDT

CFRA analyst Angelo Zino raised the price target on Oracle (NYSE: ORCL) to $142.00 (from $130.00) while maintaining a Hold rating.

The analyst comments "We increase our 12-month target to $142 from $130, on a higher revised P/E of 21x our CY 25 EPS estimate of... More

Oracle (ORCL) PT Raised to $145 at TD Cowen

March 12, 2024 6:39 AM EDT

TD Cowen analyst Derrick Wood raised the price target on Oracle (NYSE: ORCL) to $145.00 (from $130.00) while maintaining a Outperform rating.

The analyst comments "ORCL reported a solid 3Q w/ total rev growth of 7% cc in line w/ guide of 6-8%, incl.... More

Oracle (ORCL) PT Raised to $145 at Evercore ISI, 'Outlook Less Cloudy'

March 12, 2024 5:02 AM EDT

Evercore ISI analyst Kirk Materne raised the price target on Oracle (NYSE: ORCL) to $145.00 (from $130.00) while maintaining a Outperform rating.

The analyst comments "Bottom line: Oracle shares are up nicely in the after-market as OCI revenue growth of 52% in c/c was in line with our expectations and importantly, F4Q guidance infers OCI growth of ~40% against a very difficult compare. The other highlight was the strength in RPO, which grew 41% in c/c excl. Cerner to $80bn and cRPO growth of ~15%. Notably, OCI revenue grew $175mn sequentially vs. $100mn last quarter.... More

Oracle (ORCL) PT Raised to $150 at Jefferies, 'F3Q: Base Hit, One Runner On'

March 12, 2024 5:01 AM EDT

Jefferies analyst Brent Thill raised the price target on Oracle (NYSE: ORCL) to $150.00 (from $145.00) while maintaining a Buy rating.

The analyst comments "ORCL made contact in F3Q after a disappointing F1H led by better-than-expected OCI results and 29% backlog growth. While... More

Guggenheim Reviews 'Best Idea' Oracle (ORCL) Earnings

March 12, 2024 4:59 AM EDT

Guggenheim analyst John DiFucci reiterated a Buy rating and $150.00 price target on Oracle (NYSE: ORCL)

The analyst comments "ORCL surprised to the upside in OCI, and although Cloud ex. Cerner was at the low end of guidance, it was probably at least what the buy side was looking for. ORCLs results were a stark contrast to the recent decelerating business momentum of most Software names (as measured by a 2-year stack of New ARR growth see Exhibit 1). New ARR for organic Cloud accelerated to about 28% growth, and New ARR for IaaS... More

Mizuho Downgrades Acadia Pharmaceuticals (ACAD) to Neutral

March 12, 2024 4:51 AM EDT

Mizuho analyst Uy Ear downgraded Acadia Pharmaceuticals (NASDAQ: ACAD) from Buy to Neutral with a price target of $25.00 (from $39.00).

The analyst comments "Given the failed ADVANCE-2 trial, we remove our sales forecast for Nuplazid in negative symptoms of schizophrenia (NSS). With NSS... More

Oracle (ORCL) PT Raised to $159 at Bernstein, 'Solid quarter, positive outlook'

March 12, 2024 4:25 AM EDT

Bernstein analyst Mark Moerdler raised the price target on Oracle (NYSE: ORCL) to $159.00 (from $147.00) while maintaining a Outperform rating.

The analyst comments "Oracle delivered a good quarter, coming in line with expectations on total revenue, driven by a beat in cloud and software. The company also delivered a nice operating margin improvement. More importantly, Oracle provided a solid... More